radioimmunotherapy


Also found in: Wikipedia.

radioimmunotherapy

 [ra″de-o-im-mu″no-ther´ah-pe]
use of radionuclides to deliver monoclonal antibodies to targeted cancer cells.

radioimmunotherapy

[ra′dē·ōim-mu′no-ther′ah-pe]
use of radionuclides to deliver monoclonal antibodies to targeted cancer cells.

radioimmunotherapy

Immunology The use of radio-labeled–monoclonal antibodies that recognize specific antigens, and therefore concentrate in a particular tissue to treat disease Toxicity Myelosuppression, nausea, infections, cardiopulmonary toxicity

radioimmunotherapy

(rā′dē-ō-ĭm″ū-nō-thĕr′ă-pē)
The use of radioactively labeled monoclonal antibodies to treat malignancies, e.g., breast cancers, non-Hodgkin's lymphoma, and prostate cancer. The monoclonal antibodies selectively bind with antigens on the tumor cells and deliver a dose of cell-killing radiation directly to those cells.
References in periodicals archive ?
announced today that it entered into an agreement with the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg in Sweden to collaborate on the research and development of farletuzumab as an alpha therapy vector being studied for radioimmunotherapy in ovarian cancer.
Washington, Dec 04 ( ANI ): Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection.
Dr Ekaterina Dadachova and colleagues from Albert Einstein College of Medicine of the Yeshiva University in the US found that radioimmunotherapy (RIT) was successful in destroying the HIV-infected cells without affecting or causing any harm to the healthy cells.
Extremely targeted cancer- treatment - In 2011, Areva Med, working with researchers from the University of Alabama, got the green light from the US Food and Drug Administration to start a phase one clinical trial with Pb 212, using radioimmunotherapy.
It contains more than 2,000 questions and answers, updated chapters, and a new chapter of radionuclide therapy with information on radioimmunotherapy of lymphoma and Y-90 SIRT of hepatitic malignancies.
At the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), two studies were presented investigating the potential utility of Zevalin (Ibritumomab Tiuxetan) radioimmunotherapy as replacement for external beam radiations or supplement to high-dose chemotherapy in the treatment of non-Hodgkin's lymphoma (NHL).
The seven articles discuss a range of topics: anti-angiogenic strategies in hepatocellular carcinoma, rheumatoid arthritis, metronomic chemotherapy, combined radioimmunotherapy and anti-angiogenic therapy to treat cancer, quinines as anti-angiogenic agents, neovascular ocular disease, and diabetic retinopathy.
With the data showing that radioactive antibodies could selectively target and image diseases that express the specific antigens, we and other researchers focused on applying this technology to radioimmunotherapy (RAIT) of cancer.
Tokyo, Japan, July 10, 2006 - (JCN) - Nihon Schering announced on June 4 that it signed a joint business contract with Daiichi Radioisotope Laboratories (DRL) regarding Zevalin, a radioimmunotherapy agent used in the treatment of non-Hodgkin's lymphoma.
These results are exciting and further follow-up is needed to determine the long-term efficacy of combining frontline radioimmunotherapy with antibody-based maintenance.
When FL has progressed after an initial treatment regimen, radioimmunotherapy now may be considered as a second-line option.